Quantcast

Latest Vancomycin Stories

2011-02-02 20:52:24

Significantly reduces recurrence of infection, improves cure rates Clostridium difficile infection (CDI) is a significant and growing problem in hospitals and other health care facilities, but no new drugs to treat the condition have been developed in several decades. However, a large-scale, phase 3 trial conducted by Canadian and U.S. researchers shows that the new antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 percent reduction in recurrences vs. the existing...

2011-02-02 12:15:00

SAN DIEGO, Feb. 2, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only...

2011-01-24 07:00:00

SAN DIEGO, Jan. 24, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI. The FDA has also granted the Company's request for six-month Priority Review, and has assigned a Prescription Drug User Fee...

2011-01-10 06:30:00

EXTON, Pa., Jan. 10, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business and present a financial update during the 29th Annual J.P. Morgan Healthcare Conference. As previously announced, this presentation will be webcast live at 6:00 P.M. ET (3:00 P.M. PT) on Wednesday, January 12, 2011 and may be accessed via the company's website at...

2011-01-05 13:29:38

Will help physicians manage common antibiotic-resistant superbug AT A GLANCE     * The Infectious Diseases Society of America (IDSA) released its first-ever guidelines for the treatment of methicillin resistant Staphylococcus aureus (MRSA), which will help physicians determine the most appropriate care for infections due to the common bacterium.     * MRSA is the most common cause of skin infections that send people to the emergency room. Its invasive form kills...

2011-01-05 11:00:00

EXTON, Pa., Jan. 5, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 29th Annual J.P. Morgan Healthcare Conference at 6:00 P.M. ET (3:00 P.M. PT) on Wednesday, January 12, 2011. The conference is being held at the Westin St. Francis Hotel in San Francisco. ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a...

2011-01-05 07:00:00

SAN DIEGO, Jan. 5, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office has issued U.S. Patent 7,863,249 which covers additional dosage forms of fidaxomicin. This patent further strengthens Optimer's patent protection for fidaxomicin. The newly issued patent and a previously issued patent encompassing fidaxomicin are both orange book listable. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)...

2011-01-04 07:00:00

SAN DIEGO, Jan. 4, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that fidaxomicin, the Company's lead product candidate, has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of pediatric Clostridium difficile infection (CDI). This orphan drug designation applies to the active moiety and covers all formulations of fidaxomicin used to treat Clostridium difficile infection in children 16 years of age or...

2010-12-06 07:35:00

EXTON, Pa. and WEYBRIDGE, England, Dec. 6, 2010 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Idis, the global leader in developing long-term strategic solutions to therapeutic access, today announced that the two companies have partnered to facilitate access to certain ViroPharma products through a named patient program (NPP). ViroPharma's NPP, developed and managed by Idis, will allow international healthcare professionals to prescribe certain products to...

2010-11-24 10:00:00

EXTON, Pa., Nov. 24, 2010 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the 22nd Annual Piper Jaffray Healthcare Conference at 12:30 P.M. ET on Wednesday, December 1, 2010. The conference is being held at the New York Palace Hotel. Vincent Milano, president and chief executive officer of ViroPharma, will present at the 2010 Deutsche Bank BioFest Conference at...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.